hGH deficiency has a prevalence ranging from 1 in 4 000 to 1 in 15 000, and 5-30% of cases are estimated to be familial (1, 2) . Several single-gene disorders have been shown to result in IGHD with three different modes of inheritance: autosomal recessive (type I), autosomal dominant (type 11), and sex linked (type 111) (3) . Among type I patients, Illig et al. (4) described a subgroup referred to as IGHD type IA distinguished by the following characteristics: short body length at birth, early growth retardation leading to extreme dwarfism in adulthood, typical facies, strong anabolic response during an initial course of GH rapidly followed by the appearance of anti-hGH antibodies with growth arrest.
The hGH gene locus expanded during evolution into a cluster of five linked genes located on the long arm of whereas the third one maintained normal growth in the presence of very low-titer antibodies. This is the first report of a large deletional mutation within the hGH-CS gene cluster accompanied by phenotypic heterogeneity in terms of growth response and antibody formation in the different patients. (5) . The GH-1 gene codes for normal pituitary GH, whereas GH-2 encodes a peptide that differs from the pituitary GH by 13 amino acids, which is probably the so-called "human placental GH" (6) . The two CS-A and CS-B genes code for the same mature peptide and are responsible for the production of CS by the placenta (7) . The CS-L gene shares a high degree of sequence homology with the CS-A and CS-B genes but is expressed at a much lower level than the former genes in term placental tissue.
The molecular basis of type IA IGHD is a homozygous deletion of DNA containing the GH-1 structural gene. Among the cases so far reported, deletions of various size, each including the GH-1 gene, have been described. Most of those characterized are of 6.7 kb (70-80%), and the remainder are of 7.6 and 7.0 kb (8, 9) . However, a deletion of 40-kb DNA due to two separate deletions flanking the CS-L gene was detected in two affected siblings presenting with the clinical features of IGHD type IA (10) . In addition, a 45-kb gene deletion leaving intact the CS-B gene in three affected boys from a Turk-ish family (11) and two Italian siblings (12) has recently been reported.
Although in many patients the complete inborn absence of hGH is associated with immune intolerance to exogenous hGH, considerable variation in anti-hGH antibody formation and growth response is observed not only among different families, but even within families (13) . This phenotypic heterogeneity is particularly evident in those cases in which the IGHD results from small deletions within the hGH gene cluster. In fact, to date, each of the patients with large deletions developed antihGH antibodies in response to r-hGH replacement (10) (11) (12) .
The present paper describes three affected children presenting with the same 45-kb gene deletion but discordant immune and growth response to r-hGH.
METHODS

Patients
An Italian family with three affected children was studied. As shown in the pedigree in Figure 1 , the parents of patients VI-2 and VI-3 are third cousins, whereas those of patients V-2 and V-3 do not appear to be related.
Subject V-1. The girl was born in 1988 at term after a normal pregnancy. She developed without any problem and is normal for age.
Patient V-2. The second girl was born in 1990 preterm (33 wk gestation) after a pregnancy complicated by several threatened abortions. Her Apgar score at 1 and 5 min was 5-6. Her birth weight was 1450 g and length 39 cm. At the age of 4 mo, the mother suspected the same disorder as presented in her cousin (patient VI-2), and the baby was referred to our clinic. Her length was 43.7 cm (-7 SD score), weight 2890 g, and head circumference 34 cm; she was at Tanner stage I of pubertal development. On physical examination, she had the classic features of IGHD. A month later the patient died of sudden infant death syndrome before we were able to perform any hormonal or genetic study. Therefore, it can only be inferred that the baby was affected by IGHD due to hGH gene deletion.
Patient V-3. The child, a girl, was born in 1991 after a pregnancy complicated by premature labor but otherwise uneventful. Her main clinical and hormonal characteris- tics at birth and at diagnosis are reported in Table 1 . At 6 mo of age [length 49 cm (-7 SD score), height velocity 15 cmly], she was started on r-hGH therapy (3 IUIwk, divided in three doses) (Saizen, Serono, Rome, Italy). At that time no anti-hGH antibodies were detected. After 1 mo of therapy, height velocity had increased to 31.2 cmly (length 52 cm, -6 SD score) but dropped to 14 cmly at 11 mo of age (length 56.2 cm, -6.7 SD score). For that reason, hGH dosage was increased to 4 IUIwk with no major improvements. At 1.3 y of age, anti-hGH antibodies were detected with a binding capacity of 75.04 mg/L and binding affinity of 0.445 x 10 M. At her last follow-up visit, at 1.7 y of age, her length was 62.3 cm (-6.6 SD score) and weight 6330 g. The patient is now waiting to be included in an IGF-I therapeutic trial.
Subject W-1. The boy was born at term in 1980 after a normal pregnancy. He developed without any problem and is normal for age and sex.
Patient W-2. The patient, a girl, was born in 1983 by vaginal delivery to a 22-y-old woman. In Table 1 , her main clinical and hormonal characteristics are reported. r-GH treatment (Saizen, Serono) (4 IUIwk, divided in three doses) was started at 3.2 y of age and led to an increase in growth rate from 3.7 cmly to 16.8 cmly during the first year of therapy. In the following 5 y, height velocity was maintained at an average rate of 7 cmly with a r-hGH dosage adjusted to approximately 15 1u/m2. Table 1 . Main clinical and hormonal characteristics o f patients at birth and at diannosis* Patient (sex) Mean parental height (cm) Gestational age (wk) Length at birth (cm) Weight at birth (g) Age at diagnosis (y) Height at diagnosis (cm) (HSDS) Bone age at diagnosis (y) Serum GH peak levels after insulin, arginine, or clonidine stimulation (pg/L) Serum GH peak levels after GH-RH stimulation (pg/L) Baseline IGF-I serum levels (ng/mL) Baseline and ~~-~~-s t i r n u l a t ; d
Dlacental lactogen serum levels (udmLI Anti-hGH antibodies were detected shortly after the beginning of treatment but significantly declined thereafter and remained low throughout treatment with a binding capacity < 0.5 mg/L (Fig. 2) . At the last follow-up visit (chronologic age 9.9 y), the patient's height was 124.7 cm (-1.4 SD score), weight 25.5 kg, Tanner stage 11, and bone age 10.5 y; the anti-hGH antibody titer was 1:100.
Patient VI-3. The child, a boy, was born in 1986 after a normal pregnancy and labor via spontaneous vaginal delivery. Birth weight and length are reported in Table 1 . His childhood and infancy were significant for poor dietary intake, and the child has a history of seizure at 1.5 y after a prolonged period of fasting.
Growth retardation became evident during the first year of life, and the boy was referred to the hospital of his hometown at 2.5 y of age for failure to thrive. The diagnosis of hGH deficiency was made based on abnormal responses of hGH blood levels after arginine and glucagone stimulations (hGH response to pharmacologic stimulation < 10 kg/L, as reported in his records). r-hGH treatment was given (Humatrope, Lilly, Indianapolis, IN) in a dose of 12 1u1m2, divided into three injections per week. Unfortunately, no records of the patient's height before or during the 1% y of treatment are available.
The patient was referred to our clinic in 1990 while still on hGH treatment. His main clinical and hormonal characteristics at that time are reported in Table 1 . Significant anti-hGH antibody titers (1:50 000 at specific binding 50%) were detected in his serum. Methionyl r-hGH (metr-hGH, Somatonorm, Kabi-Pharmacia, Stockholm, Sweden; 16 I~l r n~, divided in four weekly doses) was substituted for methionyl-free r-hGH, similar to the one used in both of the other patients, based on the possibility that the methionine molecule bound to the N-terminal portion of the molecule, which is the most antigenic, might prevent antibody formation. This was not the case, as indicated by the very poor growth response of the patient in the following year of treatment (height velocity 2 cmly).
At the age of 6 y, he was included in an experimental therapeutic trial with recombinant IGF-I coordinated by Dr. Louis Underwood at the University of North Carolina in Chapel Hill and had excellent results in terms of growth response (14) .
Measurements
Supine length and standing height were measured with a supine measuring table and a wall-mounted stadiometer (Harpenden and Holtain Ltd., Crymmych, UK). SD scores for height were calculated based on the data of Tanner et al. (15) . Bone ages were determined using the standards of Greulich and Pyle (16) .
Serum hGH, IGF-I, and placental lactogen concentrations were measured by RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA, and Biodata, Rome, Italy).
Anti-hGH antibody titers were determined as previously described (17) . An antibody titer was defined as the plasma dilution that bound 50% of hGH tracer. Binding capacities and affinity constants were determined by Scatchard analysis using the preparation 801505 (International Reference Preparation for hGH) as standard.
Genetic Analyses
Restriction endonuclease analysis. Aliquots of highmolecular-weight nuclear DNA isolated from family members were digested with appropriate restriction endonucleases under conditions specified by the suppliers.
The digests were subjected to electrophoresis in 0.8% (wtlvol) agarose gels. The DNA fragments were then transferred to nitrocellulose membranes and hybridized with a GH-1 cDNA probe (18) or a 1.1-kb EcoRI-SstIderived genomic fragment that lies downstream from GH-1 (8) . The filters were washed and autoradiographed as previously described (10) .
DNA sequence analysis. One set of primers, S1-AS1, was used in DNA sequencing experiments. Primer S1 (TGAAATCGAAGAAAATAATAC), which is located 5' to GH-1 at position 3837-58, shows some divergences with the corresponding sequences that lie 5' to CS-A and CS-B (77 and 73% homology, respectively). The antisense primer AS1 (CCAGAGACCAGGAACATTCA) corresponds to a sequence found within the first intron of both the CS-A and CS-B genes. PCR amplification and sequencing reactions were performed as previously described (19) .
RESULTS
between the GH-1 and CS-L genes and to the 5.2 EcoRI
Therapy with r-hGH resulted in the prompt appearance of anti-hGH antibodies in all three patients. However, although the antibody titers in patients V-3 and VI-3 remained high after a variable period of time on therapy and were accompanied by an arrest in the growthpromoting effect of r-hGH, patient VI-2's antibody titer was low from the beginning and decreased further during the first year of therapy (Fig. 2) . Moreover, the latter patient showed an excellent and sustained growth response to exogenous r-hGH (Fig. 2) . She is now entering the seventh year of treatment, her height has reached the third percentile, and she has a predicted height of 149.5 cm in accordance with the target height.
Restriction endonuclease analysis demonstrated that the cause of hGH deficiency was the deletion of a large portion of the hGH gene cluster. When normal genomic DNA is digested with BamHI, six GH cDNA hybridizing fragments are obtained, ranging in size from 1.1 to 8.3 kb. The GH-1 gene is contained in a 3.8-kb fragment, the GH-2 lies in two pieces that are 1.1 and 2.9 kb in size, and the CS-G, CS-A-, and CS-B-containing fragments are 8.3, 5.3, and 6.7 kb, respectively. Analysis of patient VI-2's DNA revealed that only the 6.7-kb fragment was present (Fig. 3) . Similar results were obtained with DNA from the other two affected patients. The absence of the other fragments was associated with a deletion that removed the GH-1 gene, causing the GH deficiency, and four other genes, leaving intact the most 3' sequence, i.e. the CS-B gene. To map the deletion breakpoints, the subjects' DNA was digested with EcoRI and hybridized with an EcoRI-SstI genomic probe. This DNA piece is part of the 4.7-kb fragment located 5' to the GH-1 genecontaining fragment and contains a repeated motif that also hybridizes both to the 4.9-kb EcoRI fragment located fragment 5' to the CS-B gene. In normal subjects, three bands of 4.7, 4.9, and 5.2 kb are observed. In the patients' DNA, only the 4.7-kb band was detected (Fig. 3) . This places the deletion 5' breakpoint on the 3' side of the 4.7-kb EcoRI fragment.
PCR amplification between two sequences located on each side of the deletion breakpoint (primers S1-AS1) yielded a 1563-bp DNA fragment in the affected children and their parents, in contrast to normal controls, where no PCR product was seen. The abnormal product seen in the patients is composed of three parts: the first 1 287 nucleotides correspond to the 5' sequence of the GH-1 (from nucleotide 3 837 to 5 125), the next six bases are common to the 5' side of both the GH-1 and CS-B genes, and the remaining residues are specific to the CS-B gene sequence (from nucleotide 50 200 to 50 468) (Fig. 4) . This places the deletion breakpoint within nucleotides 5 125 to 5 130 on the 5' side and within nucleotides 50 194 to 50 199 on the 3' side of the cluster and indicates that the regulatory sequences located upstream to the TATA box of the mutant CS-B gene belong to the GH-1 gene.
DISCUSSION
The patients reported in this paper fulfilled most of the criteria for IGHD type IA, as outlined by Illig et al. (4) . In fact, all of them had short body length at birth, early and severe growth retardation, and typical facial appearance. However, they differed from each other in their anti-hGH antibody production and, consequently, their growth response to exogenous hGH. The oldest girl (VI-2), in fact, is now entering the seventh year of treatment with r-hGH and has maintained a low anti-hGH antibody titer and a satisfactory height velocity, whereas the other two children had the typical strong anabolic response to an initial course of r-hGH rapidly followed by the appearance of high-titer anti-hGH antibodies with growth arrest. Birth size in patients with IGHD type IA is extremely heterogeneous and does not seem to correlate with the deletion size, ruling out, together with other clinical and experimental evidence (20) (21) (22) (23) , a role for GH in fetal growth. The low birth weights and lengths of the patients that we studied cannot be related to the absence of the other genes of the cluster either, because patients with the same deletion previously reported (11) had normal birth weights. Moreover, the poor socioeconomic status of the family and the heavy smoking of the mothers have undoubtedly contributed to the small neonatal size.
A great phenotypic heterogeneity with respect to antibody formation has been reported in several cases of IGHD type IA described previously (13, (24) (25) (26) (27) . However, the deletion of the hGH-CS gene cluster described in one of the patients of the present study is, to our knowledge, the largest ever reported not associated with the development of anti-hGH antibodies in sufficient titer to inhibit growth. In fact, to date, each of the patients with large gene deletions reported previously (10) (11) (12) developed high-titer anti-hGH antibodies associated with immune intolerance to r-hGH replacement. Among these latter patients are those from the Turkish family carrying a 45-kb deletion similar to the one described in the present study (11) . However, because the determination of the deletion breakpoints of the mutation reported previously (11) was based on restriction endonuclease mapping only, the crossover site has not been accurately mapped within the 300 bp 5' to the GH-1 gene (and to the CS-B gene). Nevertheless, given the Mediterranean extraction of the patients from both families (Italian and Turkish), the mutant alleles may have a common origin.
The reasons for the different susceptibility to antibody formation in patients with IGHD type IA have yet to be clarified. A possible explanation is that the deletions may differ with regard to antenatal production of peptides related to hGH and, thus, to induction of immune response (27) . Alternatively, factors other than the gene deletion per se, such as different associations of the exogenous hGH with HLA-D molecules on the surface of the antigen-presenting cells (28) or different combinations of immune response genes, may contribute to this phenotypic heterogeneity.
The only gene spared by the deletion in our patients is the CS-B gene, which is responsible, as is the CS-A gene, for the production of CS, also known as placental lactogen, by the placenta. In addition to being in proximity to the GH-1 promoter, the CS-B gene has lost the "P7' region that is common to 5' regions for the placentally expressed genes and is recognized by an inhibitory transacting factor present in pituitary nuclei (29) . For this reason, human placental lactogen serum concentrations were measured at baseline and after GH-RH stimulation, but no detectable levels were found in either of the patients, ruling out the possibility that approximation of CS-B to the regulatory elements for GH-1 could result in regulated somatotrophic expression of CS-B.
TO summarize, we describe an Italian family with a 45-kb gene deletion within the hGH-CS gene cluster, encompassing the GH-1, CS-L, CS-A, and GH-2 genes. Two of the affected children developed high-titer antihGH antibodies with secondary growth arrest, whereas the third one maintained normal on hGH replacement therapy in the presence of very low-titer antibodies. Therefore, it can be concluded that the immune response to exogenous hGH is not related to the size of the deletion a i d the search for hGH gene deletion should not be confined to patients with antibody formation and subnormal growth responses, but all patients with severe growth retardation should be screened for the presence of hGH gene deletion.
